If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-27. Numbers and descriptions here follow the published literature rather than marketing material.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
=== Live data === Files that are actively being updated present a challenge to back up. One way to back up live data is to temporarily quiesce them (e.g., close all files), take a "snapshot", and then resume live operations. At this point the snapshot can be backed up through normal methods. A snapshot is an instantaneous function of some filesystems that presents a copy of the filesystem as if it were frozen at a specific point in time, often by a copy-on-write mechanism. Snapshotting a file while it is being changed results in a corrupted file that is unusable. This is also the case across interrelated files, as may be found in a conventional database or in applications such as Microsoft Exchange Server. The term fuzzy backup can be used to describe a backup of live data that looks like it ran correctly, but does not represent the state of the data at a single point in time. Backup options for data files that cannot be or are not quiesced include:
== Applications == Charged surfaces are extremely important and are used in many applications. For example, solutions of large colloidal particles depend almost entirely on repulsion due to surface charge in order to stay dispersed. If these repulsive forces were to be disrupted, perhaps by the addition of a salt or a polymer, the colloidal particles would no longer be able to sustain suspension and would subsequently flocculate.
== Soluble TCR == A soluble TCR is a TCR that has been made water-soluble using protein engineering. Such a protein is based on changing an existing TCR's chains to remove the transmembrane portions, leaving only the extracellular part. A number of techniques from protein engineering are then used to stabilize the complex and improve its binding characteristics. A soluble TCR can be used as an antigen-binding module, much like how monoclonal antibodies are used in medicine. Their advantage over antibodies is that they make use of the MHC/HLA display mechanism, allowing them to detect not only extracellular antigens, but also fragments of intracellular ones. On the other hand, they also face some restrictions in terms of applicable HLA genotypes due to them being made to target the complex of a MHC protein with the antigen fragment. One idea for overcoming this restriction is to instead target monomorphic HLA-like molecules such as HLA-E, MHC-related protein 1 (MR1) and cluster of differentiation 1 a, b, c and d (CD1a, CD1b, CD1c or CD1d). An example of a protein derived from soluble TCR is tebentafusp, approved by the US FDA in 2022. This designed protein contains a soluble TCR (αβ) targeting a fragment of gp100 presented by HLA-A*02:01 connected to a ScFv that binds CD3. As a result it causes T cells to activate in the vicinity of cells that present gp100, acting as a molecular glue (a bi-specific T-cell engager in the broad sense). It is only applicable to people with the HLA-A*02:01 genotype.
Carcinoma: Cancers derived from epithelial cells. This group includes many of the most common cancers that occur in older adults. Nearly all cancers developing in the breast, prostate, lung, pancreas, and colon are carcinomas. Sarcoma: Cancers arising from connective tissue (i.e. bone, cartilage, fat, nerve), each of which develop from cells originating in mesenchymal cells outside of the bone marrow. Lymphoma and leukemia: These two classes of cancer arise from immature cells that originate in the bone marrow, and are intended to fully differentiate and mature into normal components of the immune system and the blood, respectively. Acute lymphoblastic leukemia is the most common type of cancer in children, accounting for ~30% of cases. However, far more adults than children develop lymphoma and leukemia. Germ cell tumor: Cancers derived from pluripotent cells, most often presenting in the testicle or the ovary(seminoma and dysgerminoma, respectively). Blastoma: Cancers derived from immature "precursor" cells or embryonic tissue. Blastomas are generally more common in children (e.g. neuroblastoma, retinoblastoma, nephroblastoma, hepatoblastoma, medulloblastoma, etc.) than in older adults.
Pretreatment produces "purified water" and focuses on removing contaminants with inexpensive methods prior to reverse osmosis or ion exchange during primary treatment. Coagulation (flocculation) and settling are used along with filtration to remove particulate matter that could clog reverse osmosis filters or ion exchange resin beds. Water softening by precipitation may be used for water sources with a relatively high concentrations of dissolved salts to prevent scaling during subsequent steps. The use of coagulation, flocculation, and settling are common in municipal water treatment systems meaning pretreatment may not be necessary depending on locale. For electronics (semiconductor) applications, aluminium salts along with lime-based water softeners are used to remove silica during pre-treatment. Transition metal ions like iron and manganese can be removed through oxidation followed by precipitation/flocculation methods. After bulk chemical treatments, pretreatment may include microfiltration or ultrafiltration to remove solids. Ion-exchange resins are commonly used in the pretreament step to further reduce the amount of scale-forming ions like calcium prior to reverse osmosis treatment as scaling can easily clog reverse osmosis membranes.
Sources: en.wikipedia.org
=== Solubility === Bronopol is readily soluble in water; the dissolution process is endothermic. Solutions containing up to 28% w/v are possible at ambient temperature. Bronopol is poorly soluble in non-polar solvents but shows a high affinity for polar organic solvents.
=== Cell culture === Connecting the DMF chip to use in the field or world-to-chip interfaces have been accomplished by means of manual pumps and reservoirs which deliver microbes, cells, and media to the device. The lack of extensive pumps and valves allow for elaborate multi step applications involving cells performed in a simple and compact system. In one application, microbial cultures have been transferred onto the chip and allowed to grow with the use of sterile procedures and temperature required for microbial incubation. To validate that this was a viable space for microbial growth, a transformation assay was carried out in the device. This involves exposing E.coli to a vector and heat shocking the bacteria until they take up the DNA. This is then followed by running a DNA gel to assure that the wanted vector was taken up by the bacteria. This study found that the DNA indeed was taken up by the bacteria and expressed as predicted. Human cells have also been manipulated in Digital Microfluidic Immunocytochemistry in Single Cells (DISC) where DMF platforms were used to culture and use antibodies to label phosphorylated proteins in the cell. Cultured cells are then removed and taken off chip for screening. Another technique synthesizes hydrogels within DMF platforms. This process uses electrodes to deliver reagents to produce the hydrogel, and delivery of cell culture reagents for absorption into the gel. The hydrogels are an improvement over 2D cell culture because 3D cell culture have increased cell-cell interactions and cel-extracellular matrix interactions.
=== Pharmacokinetics === The pharmacokinetics of BRD-6929 in animals have been described. The drug penetrates into the brain in rodents. In addition, unlike vorinostat, it showed a sustained duration in the brain in rodents (t1/2 = 0.44 hours and 6.44 hours, respectively). BRD-6929 also penetrates into the brain in baboons, albeit with relatively low brain levels compared to plasma levels.
=== February === 1 February Mike Behrens, lawyer and judge, King's Counsel (since 1999), District Court judge (2004–2011) (born 1941). Dame Iritana Tāwhiwhirangi, Māori language advocate (born 1929). 2 February – Peter Babich, Hall of Fame viticulturist and businessman (born 1932). 5 February – Brian Turner, field hockey player (national team), poet and environmental campaigner, Commonwealth Poetry Prize (1999), Poet Laureate (2003–2005) (born 1944). 6 February – Jim Cole, volcanologist (University of Canterbury), Fellow of the Royal Society of New Zealand (since 2004) (born 1941). 7 February – Ian Barton, forester, heritage advocate (Queen's Redoubt Trust), and local-body politician, Franklin District Councillor (1998–2004) (born 1937). 10 February Lynne Giddings, nursing and women's studies academic (Auckland University of Technology, University of Auckland) (born 1945). Toni Huata, Māori musician (born 1969). Rod McElrea, racing driver, national beach racing champion (1971), OSCA champion (1983) (born 1941). 12 February – Theo Janssen, sculptor, stained-glass artist and painter (born 1934). 13 February – Joe Pope, business executive (Petrocorp, ENZA) and rugby administrator, chair of Hurricanes franchise (1999–2003) and Wellington Rugby Football Union (2003–2009) (born 1941). 15 February David Ellison, Māori leader (Kāti Huirapa), veterans' welfare and children's health advocate (born 1936). David Parsons, musician, composer and ethnomusicologist (born 1944). 17 February – David Saunders, lawyer and judge, District Court judge (1993–2020) (born c. 1951).
Sucrose gradient centrifugation—a linear concentration gradient of sugar (typically sucrose, glycerol, or a silica-based density gradient media, like Percoll)—is generated in a tube such that the highest concentration is on the bottom and lowest on top. A protein sample is then layered on top of the gradient and spun at high speeds in an ultracentrifuge. This causes heavy macromolecules to migrate towards the bottom of the tube faster than lighter material. During centrifugation in the absence of sucrose, as particles move farther and farther from the center of rotation, they experience more and more centrifugal force (the further they move, the faster they move). The problem with this is that the useful separation range within the vessel is restricted to a small observable window. Spinning a sample twice as long does not mean the particle of interest will go twice as far; in fact, it will go significantly further. However, when the proteins are moving through a sucrose gradient, they encounter liquid of increasing density and viscosity. A properly designed sucrose gradient will counteract the increasing centrifugal force so the particles move in close proportion to the time they have been in the centrifugal field. Samples separated by these gradients are referred to as "rate zonal" centrifugations. After separating the protein/particles, the gradient is then fractionated and collected. In biochemistry, ultracentrifugation is valuable for separating biomolecules and analyzing their physical properties.
Sources: en.wikipedia.org
== Epidemiology == A study from the Netherlands has shown an incidence of 1 in 20 million births. According to the Progeria Research Foundation, as of September 2020, there are 179 known cases in the world, in 53 countries; 18 of the cases were identified in the United States. Hundreds of cases have been reported in medical history since 1886. However, the Progeria Research Foundation believes there may be as many as 150 undiagnosed cases worldwide. There have been only two cases in which a healthy person was known to carry the LMNA mutation that causes progeria. One family from India had four of six children with progeria.
=== Pharmacokinetics === Alexander Shulgin has noted that 6-HO-DET may have poor blood–brain barrier permeability due to its exposed hydroxyl group and consequent polarity analogously to bufotenin (5-HO-DMT).
== Research == Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders. As of September 2025, it has reached phase 2 clinical trials for these indications. A phase 3 trial is planned for 2026. The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).
A myocardial infarction induces tissue remodeling of the heart in a three-phase process: inflammation, proliferation, and maturation. Inflammation is characterized by massive necrosis in the infarcted area. Inflammatory cells clear the dead cells. In the proliferation phase, inflammatory cells die by apoptosis, being replaced by myofibroblasts which produce large amounts of collagen. In the maturation phase, myofibroblast numbers are reduced by apoptosis, allowing for infiltration by endothelial cells (for blood vessels) and cardiomyocytes (heart tissue cells). Usually, however, much of the tissue remodeling is pathological, resulting in a large amount of fibrous tissue. By contrast, aerobic exercise can produce beneficial cardiac tissue remodeling in those suffering from left ventricular hypertrophy. Programmed cellular senescence contributes to beneficial tissue remodeling during embryonic development of the fetus. In a brain stroke the penumbra area surrounding the ischemic event initially undergoes a damaging remodeling, but later transitions to a tissue remodeling characterized by repair. Vascular remodeling refers to a compensatory change in blood vessel walls due to plaque growth. Vascular expansion is called positive remodeling, whereas vascular constriction is called negative remodeling. Tissue remodeling occurs in adipose tissue with increased body fat. In obese subjects, this remodeling is often pathological, characterized by excessive inflammation and fibrosis.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.